Friday, 25 September 2026European Markets

MYHOTELMATCH Stock Bullish Momentum With A 17.68% Rise On Thursday

Loading stream...

(vianews) - the market ended the session with myhotelmatch (mhm.pa) rising 17.68% to €0.99 on thursday, after four sequential sessions in a row of losses. cac 40 fell 0.1% to €7,428.52, after two sequential sessions in a row of gains, on what was a somewhat down trend exchanging session today.

myhotelmatch's last close was €0.84, 78.32% under its 52-week high of €3.88.

about myhotelmatch

myhotelmatch s.a. engages in the development of an online hotel reservation platform based on artificial intelligence (ai). it operates as an online travel agency based on the principle of online dating. myhotelmatch s.a. was incorporated in 2010 and is headquartered in biot, france.

earnings per share

as for profitability, myhotelmatch has a trailing twelve months eps of €-1.34.

yearly top and bottom value

myhotelmatch's stock is valued at €0.99 at 21:31 est, way under its 52-week high of €3.88 and way above its 52-week low of €0.79.

moving average

myhotelmatch's value is way under its 50-day moving average of €1.16 and way below its 200-day moving average of €2.07.

volume

today's last reported volume for myhotelmatch is 52076 which is 186.85% above its average volume of 18154.

more news about myhotelmatch (mhm.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com